Forman JP, Rimm EB, Stampfer MJ, Curhan GC
Clinical Studies and Evidence SUSTAIN-6 Trial (Cardiovascular Outcomes) Published in the New England Journal of Medicine (2016), the SUSTAIN-6 trial demonstrated that Semaglutide significantly reduced the risk of major adverse cardiovascular events (MACE) cardiovascular death, non-fatal myocardial infarction, and non-fatal stroke by 26% compared to placebo in patients with Type 2 diabetes and high cardiovascular risk
Key molecular targets and outputs
Semaglutide is FDA-approved and clinically proven to be both safe and effective when prescribed and monitored by licensed providers
Pre-Workout: For endurance and strength enhancement, take L-Carnitine about 30 to 60 minutes before your workout
Always inject at least 1 inch away from your last spot to give the tissue enough time about 4 to 6 weeks to recover